TNF Pharmaceuticals (NASDAQ:TNFA – Get Free Report) and One Stop Systems (NASDAQ:OSS – Get Free Report) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of One Stop Systems shares are held by institutional investors. 0.4% of TNF Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of One Stop Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for TNF Pharmaceuticals and One Stop Systems, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TNF Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| One Stop Systems | 1 | 1 | 3 | 1 | 2.67 |
Volatility & Risk
TNF Pharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, One Stop Systems has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.
Profitability
This table compares TNF Pharmaceuticals and One Stop Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TNF Pharmaceuticals | N/A | -69.21% | -33.98% |
| One Stop Systems | 2.67% | 2.22% | 1.71% |
Earnings and Valuation
This table compares TNF Pharmaceuticals and One Stop Systems”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TNF Pharmaceuticals | N/A | N/A | -$23.36 million | ($231.00) | -0.01 |
| One Stop Systems | $32.22 million | 8.55 | $5.09 million | $0.05 | 220.80 |
One Stop Systems has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than One Stop Systems, indicating that it is currently the more affordable of the two stocks.
Summary
One Stop Systems beats TNF Pharmaceuticals on 13 of the 14 factors compared between the two stocks.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
About One Stop Systems
One Stop Systems, Inc. engages in the design, manufacture, and marketing of high-performance compute, high speed storage hardware and software, switch fabrics, and systems for edge deployments in the United States and internationally. The company's systems are built using the central processing unit, graphical processing unit, high-speed switch fabrics, and flash storage technologies. It provides custom servers, data acquisition platforms, compute accelerators, solid-state storage arrays, and system I/O expansion systems, as well as edge optimized industrial and panel PCs, tablets, and handheld compute devices. The company also offers ruggedized mobile tablets and handhelds that meet the specialized requirement for devices deployed at the edge in a diverse set of environmental conditions. It sells its products to multinational companies, governmental agencies, military contractors, military services, and technology providers through its website, web store, direct sales team, and original equipment manufacturer focused sales, as well as through a network of resellers and distributors. The company was founded in 1998 and is headquartered in Escondido, California.
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
